Scots say yes to cancer drugs after patients have their say
This article was originally published in Scrip
Executive Summary
Using a new process that involves greater patient input, Scotland's health technology appraisal body, the Scottish Medicines Consortium, has okayed for use on the local NHS three anticancers that England has so far largely rejected for use on its NHS. Ariad's Iclusig (ponatinib), Boehringer Ingelheim's Vargatef (nintedanib) and Bayer's Stivarga (regorafenib) have all been given the green light in Scotland.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.